Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective
Cancers · 08.02.2024 · 16 (4) · 723
DOI: 10.3390/cancers16040723 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.02.2024. Verfasst von Hiroshi Hayashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu 183-8561, Tokyo, Japan. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute lymphoblastic leukemia (ALL) is the most common disease in pediatric oncology. The history of developmental therapeutics for ALL began in the 1960s with the repetition of “unreliable” medical interventions against this lethal disease. By the 1990s, the development of multi-agent chemotherapy and various types of supportive care rendered ALL treatable. Highly sophisticated, molecular, diagnostic techniques have enabled highly accurate prediction of the relapse risk, and the application of risk-adapted treatments has increased the survival rate in the standard-risk group to nearly 100% in most European nations and North America. Incorporation of state-of-the-art, molecularly targeted agents and novel treatments, including cell and immunotherapy, is further improving outcomes even in the high-risk group. On the other hand, the financial burden of treating children with ALL has increased, imperiling the availability of these diagnostic and treatment strategies to patients in low- and middle-income countries (LMICs). The fundamental treatment strategy, consisting of corticosteroid and classical cytotoxic therapy, has achieved fairly good outcomes and should be feasible in LMICs as well. The present review will discuss the history of developmental therapeutics for childhood ALL in various countries through an extensive literature review with the aim of proposing a model for a treatment backbone for pediatric ALL. The discussion will hopefully benefit LMICs and be useful as a base for future clinical trials of novel treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu 183-8561, Tokyo, Japan.
- Department of Laboratory Medicine, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu 183-8561, Tokyo, Japan.
ORCID-Profile: Hiroshi Hayashi, Atsushi Makimoto
Zitieren
APA
Hayashi, H., Makimoto, A., & Yuza, Y. (2024). Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective. Cancers, 16(4), 723. https://doi.org/10.3390/cancers16040723
Vancouver
Hayashi H, Makimoto A, Yuza Y. Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective. Cancers. 2024;16(4):723. doi:10.3390/cancers16040723
BibTeX
@article{Hayashi2024,
author = {Hayashi, Hiroshi and Makimoto, Atsushi and Yuza, Yuki},
title = {Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {723},
doi = {10.3390/cancers16040723}
}
EUVIMED